Agenus Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/25/2026)
| Balance Sheet | Total Assets | 226,798,000.00 | ROE | -119.54 % |
| Balance Sheet | Total Equity | -271,111,000.00 | ROA | -1.36 % |
| Cashflow | Capital Expenditures | -6,000.00 | P/FCF | -2.50 |
| Cashflow | Free Cash Flow | -77,201,000.00 | – | – |
| Cashflow | Operating Cash Flow | -77,195,000.00 | P/CF | -2.50 |
| Income | Earnings per Share (diluted) | -0.10 | Div. Yield | – |
| Income | Net Income | -3,083,000.00 | P/E | -65.00 |
| Income | Shares Outstanding | 29,734,000.00 | P/B | -0.71 |
| Income | Total Revenue | 114,196,000.00 | P/S | 1.69 |
Ratios calculated on: 10/14/2026
Company Description
Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP)-based vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.agenusbio.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more